HDAC inhibitor-based therapies: can we interpret the code?
Abnormal epigenetic control is a common early event in tumour progression, and aberrant acetylation in particular has been implicated in tumourigenesis. One of the most promising approaches towards drugs that modulate epigenetic processes has been seen in the development of inhibitors of histone dea...
| Huvudupphovsmän: | , , |
|---|---|
| Materialtyp: | Journal article |
| Språk: | English |
| Publicerad: |
2012
|
| _version_ | 1826307169961639936 |
|---|---|
| author | New, M Olzscha, H La Thangue, N |
| author_facet | New, M Olzscha, H La Thangue, N |
| author_sort | New, M |
| collection | OXFORD |
| description | Abnormal epigenetic control is a common early event in tumour progression, and aberrant acetylation in particular has been implicated in tumourigenesis. One of the most promising approaches towards drugs that modulate epigenetic processes has been seen in the development of inhibitors of histone deacetylases (HDACs). HDACs regulate the acetylation of histones in nucleosomes, which mediates changes in chromatin conformation, leading to regulation of gene expression. HDACs also regulate the acetylation status of a variety of other non-histone substrates, including key tumour suppressor proteins and oncogenes. Histone deacetylase inhibitors (HDIs) are potent anti-proliferative agents which modulate acetylation by targeting histone deacetylases. Interest is increasing in HDI-based therapies and so far, two HDIs, vorinostat (SAHA) and romidepsin (FK228), have been approved for treating cutaneous T-cell lymphoma (CTCL). Others are undergoing clinical trials. Treatment with HDIs prompts tumour cells to undergo apoptosis, and cell-based studies have shown a number of other outcomes to result from HDI treatment, including cell-cycle arrest, cell differentiation, anti-angiogenesis and autophagy. However, our understanding of the key pathways through which HDAC inhibitors affect tumour cell growth remains incomplete, which has hampered progress in identifying malignancies other than CTCL which are likely to respond to HDI treatment. |
| first_indexed | 2024-03-07T06:58:54Z |
| format | Journal article |
| id | oxford-uuid:ff1286dd-dfa7-4f67-bc30-8ab1e4ae6c46 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T06:58:54Z |
| publishDate | 2012 |
| record_format | dspace |
| spelling | oxford-uuid:ff1286dd-dfa7-4f67-bc30-8ab1e4ae6c462022-03-27T13:41:40ZHDAC inhibitor-based therapies: can we interpret the code?Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:ff1286dd-dfa7-4f67-bc30-8ab1e4ae6c46EnglishSymplectic Elements at Oxford2012New, MOlzscha, HLa Thangue, NAbnormal epigenetic control is a common early event in tumour progression, and aberrant acetylation in particular has been implicated in tumourigenesis. One of the most promising approaches towards drugs that modulate epigenetic processes has been seen in the development of inhibitors of histone deacetylases (HDACs). HDACs regulate the acetylation of histones in nucleosomes, which mediates changes in chromatin conformation, leading to regulation of gene expression. HDACs also regulate the acetylation status of a variety of other non-histone substrates, including key tumour suppressor proteins and oncogenes. Histone deacetylase inhibitors (HDIs) are potent anti-proliferative agents which modulate acetylation by targeting histone deacetylases. Interest is increasing in HDI-based therapies and so far, two HDIs, vorinostat (SAHA) and romidepsin (FK228), have been approved for treating cutaneous T-cell lymphoma (CTCL). Others are undergoing clinical trials. Treatment with HDIs prompts tumour cells to undergo apoptosis, and cell-based studies have shown a number of other outcomes to result from HDI treatment, including cell-cycle arrest, cell differentiation, anti-angiogenesis and autophagy. However, our understanding of the key pathways through which HDAC inhibitors affect tumour cell growth remains incomplete, which has hampered progress in identifying malignancies other than CTCL which are likely to respond to HDI treatment. |
| spellingShingle | New, M Olzscha, H La Thangue, N HDAC inhibitor-based therapies: can we interpret the code? |
| title | HDAC inhibitor-based therapies: can we interpret the code? |
| title_full | HDAC inhibitor-based therapies: can we interpret the code? |
| title_fullStr | HDAC inhibitor-based therapies: can we interpret the code? |
| title_full_unstemmed | HDAC inhibitor-based therapies: can we interpret the code? |
| title_short | HDAC inhibitor-based therapies: can we interpret the code? |
| title_sort | hdac inhibitor based therapies can we interpret the code |
| work_keys_str_mv | AT newm hdacinhibitorbasedtherapiescanweinterpretthecode AT olzschah hdacinhibitorbasedtherapiescanweinterpretthecode AT lathanguen hdacinhibitorbasedtherapiescanweinterpretthecode |